DNA Damage Response in Prostate Cancer.
Cold Spring Harb Perspect Med
; 9(1)2019 01 02.
Article
en En
| MEDLINE
| ID: mdl-29530944
ABSTRACT
Prostatic adenocarcinoma (PCa) remains a significant health concern. Although localized PCa can be effectively treated, disseminated disease remains uniformly fatal. PCa is reliant on androgen receptor (AR); as such, first-line therapy for metastatic PCa entails suppression of AR signaling. Although initially effective, recurrent tumors reactivate AR function, leading to a lethal stage of disease termed castration-resistant PCa (CRPC). Recent findings implicate AR signaling in control of DNA repair and show that alterations in DNA damage repair pathways are strongly associated with disease progression and poor outcome. This review will address the DNA repair alterations observed in the clinical setting, explore the anticipated molecular and cellular consequence of DNA repair dysfunction, and consider clinical strategies for targeting tumors with altered DNA repair.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Daño del ADN
/
Adenocarcinoma
/
Transformación Celular Neoplásica
/
Reparación del ADN
Límite:
Humans
/
Male
Idioma:
En
Revista:
Cold Spring Harb Perspect Med
Año:
2019
Tipo del documento:
Article